TUESDAY, March 29, 2022 (HealthDay News) — Despite months of intense lobbying by patient advocates, federal health officials on Monday posted a largely negative review of an experimental drug for the devastating illness known as amyotrophic lateral sclerosis (ALS). In an analysis of Amylyx Pharmaceuticals’ drug, known for now onlyContinue Reading

MONDAY, March 28, 2022 (HealthDay News) — Special needs children often require out-of-network care from specialists, which means more out-of-pocket costs and extra stress for families, a new study finds. “In the U.S., the reality is that the more health care needs you have, especially from specialists, the greater chanceContinue Reading